A number of epidemiological studies demonstrated thatNSAID treatment reduces AD risk by as much as 80% and it was suggested thatthese effects arise from the ability of these drugs to stimulate PPARγ and toinhibit inflammatory responses in the AD brain [41–45]. This evidence concerns the gene PPARG and Alzheimer disease.